Flatiron Health Presents Research at ISPOR Europe

Focus is on Potential of Real-World Data to Support HTA Decisions

NEW YORK, November 29, 2021

Flatiron Health is presenting results from its research collaboration with the National Institute for Health and Care Excellence (NICE) at Virtual ISPOR Europe 2021

In the study Exploring the Potential for EHR-Derived Real-World Data to Reduce Uncertainty in HTA Decision-Making: A Case Study of Long-Term Survival Outcomes, presented in an On-Demand Podium Session, researchers from Flatiron and NICE investigated how real-world data (RWD) may complement findings from clinical trials to reduce uncertainties in Health Technology Appraisal (HTA) decision-making. In this case, the investigators focused on an immunotherapy drug in advanced lung cancer to see if RWD could have been used to address uncertainty regarding long-term survival.

Leveraging Flatiron electronic-health-record (EHR)-derived data from approximately 70,000 U.S. patients with non-small cell lung cancer (NSCLC), the investigators identified a cohort of 1,109 patients with previously untreated, Stage IV NSCLC, with positive or unknown PDL1 status, who initiated first-line pembrolizumab monotherapy between October 2016 and December 2020. They also applied additional lab and ECOG eligibility criteria, using RWD to define a cohort that reflected as much as possible that of the clinical trial. Reported results showed a median real-world median overall survival of 13.8 months.

“This study examined one approach by which we may be able to augment clinical trial data to inform important decisions, such as clinical and cost effectiveness of new technologies and medicines,” said Michael Vasconcelles, MD, Chief Medical Officer and Head of the Medical and Scientific Organization at Flatiron. “I look forward to continuing our research collaboration with NICE to further our understanding of the optimal use of RWD in this regard.”

The three-year Flatiron-NICE research collaboration was launched in July 2020 to explore how RWD may inform the clinical and cost effectiveness of health technologies. Research presented in May at ISPOR 2021 looked at whether RWD available in the U.S. following approval by the Food and Drug Administration could inform NICE technology appraisals for the same medicine and proposed use

Also at ISPOR Europe, on December 1, scientists from Flatiron, NICE and Roche will conduct a workshop, Policy and Statistical Issues in HTA Review of Histology-Independent Technologies (HIT) in Oncology, offering HTA and industry perspectives about research questions and evidence gaps in health information technology assessments.

About Flatiron

Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth